Postnatal calpain inhibition elicits cerebellar cell death and motor dysfunction
PDF | HTML | How to cite
Metrics: PDF 1106 views | HTML 2425 views | ?
Junyao Li1, Sanjuan Yang1 and Guoqi Zhu1
1Key Laboratory of Xin’an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230038, China
Guoqi Zhu, email: [email protected]
Keywords: postnatal, calpain inhibition, cerebellum, apoptosis, motor dysfunction
Abbreviations: SBPs: spectrin breakdown products; RFU: relative fluorescence unit; p-Akt: phosphorylated protein kinase B; SCOP: suprachiasmatic nucleus circadian oscillatory protein.
Received: July 25, 2017 Accepted: August 29, 2017 Published: September 27, 2017
Calpain-1 deletion elicits neurodevelopmental disorders, such as ataxia. However, the function of calpain in postnatal neurodevelopment and its mechanisms remain unknown. In this study, we revealed that postnatal intraperitoneal injection of various calpain inhibitors attenuated cerebellar cytosolic calpain activity. Moreover, postnatal application of calpeptin (2 mg/kg) apparently reduced spectrin breakdown, promoted suprachiasmatic nucleus circadian oscillatory protein (SCOP) accumulation in cerebellar tissue. In addition, application of calpeptin decreased phosphorylated protein kinase B (p-AKT) level (p<0.05), as well as total AKT level (p<0.05). We also evidenced that administration of calpeptin obviously increased phosphorylation of mammalian target of rapamycin (p-mTor) (p<0.01). Apoptosis of granular cells and activation of caspase-3 (p<0.01) were facilitated after calpain inhibition. Importantly, cell numbers of granular cells were reduced and motor function was remarkably impaired in 4-month-old rats receiving postnatal calpain inhibition. Taken together, our data implicated that calpain activity in the postnatal period was critical for the cerebellar development. Postnatal calpain inhibition causes cerebellar granular cell apoptosis and motor dysfunction, likely through SCOP/AKT and p-mTor signaling pathways.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.